

**3.2.P.1. DESCRIPTION AND COMPOSITION OF THE DRUG PRODUCT**

The BNT162b2 drug product is supplied as a preservative-free, multi-dose concentrate to be diluted for intramuscular injection, containing 6 doses. The drug product is a sterile dispersion of RNA-containing lipid nanoparticles (LNPs) in aqueous cryoprotectant buffer.

Each vial, containing 0.45 mL of the drug product at pH 7.4 is designed to contain a total of 6 doses after dilution by addition of 1.8 mL of sterile 0.9% sodium chloride solution, with each dose containing 30 µg of RNA in 0.3 mL. There is no manufacturing overage.

The drug product is supplied in a 2 mL glass vial sealed with a bromobutyl rubber stopper and an aluminum seal with flip-off plastic cap.

The composition of the drug product, including amounts per vial and function and quality standard applicable to each component, are given in [Table 3.2.P.1-1](#).

**Table 3.2.P.1-1. Composition of BNT162b2 Drug Product, multi-dose vial (225 µg/vial)**

Name of Ingredients	Reference to Standard	Function	Concentration (mg/mL)	Amount per vial	Amount per dose
BNT162b2 drug substance	In-house specification	Active ingredient	0.5	225 µg	30 µg
ALC-0315	In-house specification	Functional lipid	7.17	3.23 mg	0.43 mg
ALC-0159	In-house specification	Functional lipid	0.89	0.4 mg	0.05 mg
DSPC	In-house specification	Structural lipid	1.56	0.7 mg	0.09 mg
Cholesterol	Ph. Eur.	Structural lipid	3.1 <sup>a</sup>	1.4 mg	0.2 mg
Sucrose	Ph. Eur.	Cryoprotectant	103 <sup>a</sup>	46 mg	6 mg
Sodium chloride	Ph. Eur.	Buffer component	6	2.7 mg	0.36 mg
Potassium chloride	Ph. Eur.	Buffer component	0.15	0.07 mg	0.01 mg
Dibasic sodium phosphate, dihydrate <sup>b</sup>	Ph. Eur.	Buffer component	1.08	0.49 mg	0.07 mg
Monobasic potassium phosphate <sup>c</sup>	Ph. Eur.	Buffer component	0.15	0.07 mg	0.01 mg
Sodium hydroxide	Ph. Eur.	Buffer pH adjustment	q.s. <sup>d</sup>		
Hydrochloric acid	Ph. Eur.	Buffer pH adjustment	q.s. <sup>d</sup>		
Water for Injection	Ph. Eur.	Solvent/vehicle	q.s.	q.s.	q.s.
<b>Processing Aids/Residues<sup>e</sup></b>					
Ethanol	Ph. Eur.	Processing aid	N/A		
Citric acid monohydrate	Ph. Eur.	Processing aid			
Sodium citrate	Ph. Eur.	Processing aid			
Sodium hydroxide	Ph. Eur.	Processing aid			
HEPES	In-house specification	Drug substance buffer component			
EDTA	Ph. Eur., USP-NF	Drug substance buffer component			

a. Values are rounded to maintain the same level of precision as the label claim, with trailing zeros not shown, where applicable. For example, 46 mg sucrose is rounded from 46.35 mg (103 mg/mL).

b. Dibasic sodium phosphate, dihydrate is named as disodium phosphate dihydrate in the Ph. Eur.

c. Monobasic potassium phosphate is named as potassium dihydrogen phosphate in the Ph. Eur.

d. May be used to adjust buffer to target pH.

e. The processing aids and drug substance formulation buffer components are residues that are essentially removed through the manufacturing process are not considered ingredients (excipients).

Abbreviations:

ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)

ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide

DSPC = 1,2-distearoyl-sn-glycero-3-phosphocholine

q.s. = quantum satis (as much as may suffice)

HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

EDTA = edetate disodium dihydrate